Plitidepsin

Drug Profile

Plitidepsin

Alternative Names: Aplidin; Aplidine; DDB; Dehydrodidemnin B

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator PharmaMar
  • Class Antineoplastics; Depsipeptides
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Protein synthesis inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Acute lymphoblastic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma; Multiple myeloma; Peripheral T-cell lymphoma

Highest Development Phases

  • Preregistration Multiple myeloma
  • Phase II Non-Hodgkin's lymphoma; T cell lymphoma
  • Phase I Solid tumours
  • No development reported Liposarcoma; Malignant melanoma; Myelofibrosis
  • Discontinued Leukaemia; Prostate cancer

Most Recent Events

  • 28 Oct 2016 The European Medicines Agency accepts MAA for plitidepsin for Multiple myeloma (Combination therapy) for review
  • 04 Oct 2016 Plitidepsin licensed to Boryung Pharm in South Korea for commercialisation
  • 22 Sep 2016 Preregistration for Multiple myeloma (Combination therapy) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top